<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01026272</url>
  </required_header>
  <id_info>
    <org_study_id>35083-B</org_study_id>
    <secondary_id>A50879</secondary_id>
    <nct_id>NCT01026272</nct_id>
  </id_info>
  <brief_title>Novel Immune Markers in Patients With Multiple Sclerosis</brief_title>
  <acronym>NIMMS</acronym>
  <official_title>Quantification of Novel Immune Markers in Human Serum of Patients With MS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that the endogenous cannabinoid signalling system has lost&#xD;
      homeostasis in the disease multiple sclerosis (MS). To investigate a novel action of dietary&#xD;
      fish oils, the investigators will administer a food frequency questionnaire to both healthy&#xD;
      subjects and patients with MS. The investigators will first determine if there are&#xD;
      differences between both populations of endogenous cannabinoids, and then determine whether&#xD;
      dietary intake of fish oils alters these levels&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">May 2011</completion_date>
  <primary_completion_date type="Anticipated">January 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of endogenous cannabinoids</measure>
    <time_frame>one time blood draw</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Monocyte migration</measure>
    <time_frame>one time blood draw</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>healthy subjects</arm_group_label>
    <description>subjects with no sign of inflammatory disease, or diagnosis of MS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with MS</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Multiple Sclerosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion Criteria for MS patients:&#xD;
&#xD;
          1. Diagnosis of Multiple Sclerosis (relapsing, remitting) made by a clinical neurologist&#xD;
             within the previous 5 years by either MRI (&gt; 3 white matter lesions) or score of 3-5&#xD;
             on the Kurtzke Expanded Disability Status Scale.&#xD;
&#xD;
          2. Not currently in &quot;relapse&quot; or exacerbation.&#xD;
&#xD;
          3. Age &gt; 21 and &lt; 50.&#xD;
&#xD;
          4. Subjects must be able to attend study visits at screening, baseline and time points of&#xD;
             4, 12 and 24 weeks.&#xD;
&#xD;
          5. Diet, exercise, and supplementation must be kept constant throughout participation in&#xD;
             the study.&#xD;
&#xD;
          6. Ability to read and speak English.&#xD;
&#xD;
        Inclusion criteria for healthy subjects:&#xD;
&#xD;
          1. Current.&#xD;
&#xD;
          2. Age &gt; 21 and &lt; 50.&#xD;
&#xD;
          3. Subjects must be able to attend study visits at screening, baseline and time points 4,&#xD;
             12 and 24 weeks.&#xD;
&#xD;
          4. Diet, exercise, and supplementation must be kept constant throughout participation in&#xD;
             the study.&#xD;
&#xD;
          5. Ability to read and speak English.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Supplementation with fish oils in the last six months.&#xD;
&#xD;
          2. Diagnosis of any bleeding disorder (hemophilia, vonWillebrands, menorrhagia,&#xD;
             hypercoaguability, history of clots, thrombocytopenia). Any patient with one of these&#xD;
             diagnoses and/or any patient on any of/combination of the following medications would&#xD;
             not be eligible for participation: ANTICOAGULANT/ANTIPLATELET DRUGS: Some of these&#xD;
             drugs include aspirin, clopidogrel (Plavix), dalteparin (Fragmin), dipyridamole&#xD;
             (Persantine), enoxaparin (Lovenox), heparin, ticlopidine (Ticlid), warfarin&#xD;
             (Coumadin).&#xD;
&#xD;
          3. Hormone Replacement Therapy or oral contraception pills or pregnancy.&#xD;
&#xD;
          4. Use of clinical Cannabis for MS symptom control or recreationally in the last 6&#xD;
             months.&#xD;
&#xD;
          5. Previous diagnosis of DSMV criteria.&#xD;
&#xD;
          6. Use of tobacco, either orally or inhaled.&#xD;
&#xD;
          7. BMI &gt;27 or &lt;19.&#xD;
&#xD;
          8. Diagnosis of Diabetes (fasting blood sugar over 125 mg/dl).&#xD;
&#xD;
          9. Performance athletes.&#xD;
&#xD;
         10. Medical history/diagnosis of autoimmune or other chronic inflammatory disease or&#xD;
             serious immunologically-related health condition.&#xD;
&#xD;
         11. Lactose intolerance (in-ability to eat/drink milk products without problems).&#xD;
&#xD;
         12. Allergy to fish or seafood. Theoretically, some people who are allergic to seafood&#xD;
             such as fish might also be allergic to fish oil supplements. There is no reliable&#xD;
             information showing how likely people with seafood allergy are to have an allergic&#xD;
             reaction to fish oils; however, until more is known advise patients allergic to&#xD;
             seafood to avoid or use fish oil supplements cautiously.&#xD;
&#xD;
         13. High dose supplement/botanical therapy which may have an effect on bleeding times:&#xD;
             Vitamin E (greater than 400 IU/qd); adn/or daily use of any/combination of the&#xD;
             following botanical therapy: Angelica sinensis; Allium sativum; Zingiber officinale;&#xD;
             Ginkgo biloba; and Salix alba.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle Sexton, ND</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Sexton, ND</last_name>
      <phone>206-538-3896</phone>
      <email>msexton@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Michelle Sexton, ND</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Sexton, ND</last_name>
      <phone>206-543-3896</phone>
      <email>msexton@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Michelle Sexton, ND</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <study_first_submitted>December 2, 2009</study_first_submitted>
  <study_first_submitted_qc>December 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2009</study_first_posted>
  <last_update_submitted>July 9, 2010</last_update_submitted>
  <last_update_submitted_qc>July 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Michelle Sexton ND</name_title>
    <organization>University of Washington</organization>
  </responsible_party>
  <keyword>Endocannabinoid</keyword>
  <keyword>Fish Oil</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Monocyte Migration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>May 15, 2017</submitted>
    <returned>October 10, 2017</returned>
    <submitted>December 8, 2017</submitted>
    <returned>October 4, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

